The Defense-Tech Startup Reinventing Military Logistics | Brandon Florian - Co-Founder and Chief Commercial Officer - Grid Aero

Send us Fan MailPharma has spent decades building a graveyard of failed drugs — but hidden inside that data may be treatments that actually worked… for someone.Vin Singh is Founder and CEO of BullFrog AI ( https://bullfrogai.com/ ), a company working at the intersection of machine learning, causal modeling, and drug development.BullFrog is focused on a fundamental problem in biopharma — not just how to analyze increasingly large datasets, but how to extract meaningful cause-and-effect relationships from them. Their platform integrates data preparation, analysis, and network-based modeling to help research teams better understand biological mechanisms, identify patient subgroups, and improve clinical trial design.Vin brings a deep mix of technical, operational, and entrepreneurial experience to this challenge. Prior to founding BullFrog, he held leadership roles across the life sciences ecosystem, including serving as Global Director of the Cell Therapy Business at Thermo Fisher Scientific, where he oversaw services supporting clinical and commercial-stage therapies. He also founded and led Next Healthcare, a company focused on adult stem cell and skin cell banking, and was an early co-founder at MaxCyte, helping build foundational technologies in cell engineering.In addition to his operating roles, Vin has been active in the innovation ecosystem as a Mentor in Residence at Johns Hopkins Technology Ventures.Vin holds an MBA in Finance from Johns Hopkins University, a Master’s in Biomedical Engineering from Rensselaer Polytechnic Institute, and a Bachelor’s in Electrical Engineering from Rutgers University — a background that spans engineering, biology, and business.#CausalAI #DrugDevelopment #Biotech #ClinicalTrials #PrecisionMedicine #AIinHealthcare #PharmaInnovation #FailedDrugs #OncologyResearch #PancreaticCancer #FutureOfMedicine #MachineLearning #Biopharma #TranslationalMedicine #DigitalHealth #MedicalInnovation #DataScience #ClinicalResearch #AIinBiotech #HealthcareInnovationSupport the show

Send us Fan MailBone marrow transplants have always depended on finding the right donor at the right time. But what if bone marrow could be stored, shipped, and used on demand—just like a drug? That’s exactly what Ossium Health is now showing in human clinical data.Kevin Caldwell is the Co-Founder, CEO, and President of Ossium Health ( https://ossiumhealth.com/ ), a clinical-stage bioengineering company pioneering off-the-shelf, cryopreserved bone marrow therapies derived from deceased organ donors.Under Kevin’s leadership, Ossium has developed a novel platform designed to solve one of the most persistent challenges in transplantation medicine: timely access to compatible bone marrow for patients with life-threatening hematologic malignancies such as Acute Myeloid Leukemia. The company’s approach enables on-demand delivery of viable marrow cells, bypassing the logistical and biological constraints of traditional donor matching and scheduling.Since its founding, Kevin has scaled Ossium from an early-stage startup into a clinical-stage company with a robust network of over 50 strategic partnerships across supply, clinical development, and commercial channels. He has led multiple financings and secured a landmark contract with the Biomedical Advanced Research and Development Authority, validating Ossium’s relevance to national health preparedness and biomanufacturing resilience.Most recently, Kevin has overseen the company’s transition into human clinical validation, including first-in-human data from the PRESERVE I trial, real-world use cases in transplant rescue scenarios, and peer-reviewed publication of its GMP-based manufacturing platform and early outcomes.Prior to founding Ossium, Kevin was an Engagement Manager at McKinsey & Company, advising biotech and healthcare companies on strategy, M&A, and restructuring. Earlier, he worked in quantitative research at Bridgewater Associates. He holds degrees in Physics and Economics from MIT and a JD from Harvard Law School.#Biotech #BoneMarrowTransplant #StemCells #CancerTreatment #Leukemia #AML #CellTherapy #RegenerativeMedicine #Biotechnology #FutureOfMedicine #HealthcareInnovation #MedicalBreakthrough #Immunotherapy #TransplantMedicine #Cryopreservation #LongevityScience #Bioengineering #StartupScience #OnDemandMedicine #PrecisionMedicine #ClinicalTrials #Biopharma #DeepTech #LifeSciences #HealthcareDisruptionSupport the show

Send us Fan MailThere’s an entire medical specialty, Physiatry, dedicated not to treating disease - but to helping patients regain their lives. And most people have never heard of it.Dr. Michael Yochelson is a Physiatrist and a nationally recognized leader in rehabilitation medicine and brain injury care ( https://shepherd.org/staff-directory/michael-yochelson/ ).Dr. Yochelson serves as the Chief Medical Officer at Shepherd Center, one of the top hospitals in the United States for spinal cord and brain injury rehabilitation. He is also an Adjunct Professor at Emory University School of Medicine ( https://med.emory.edu/directory/profile/?u=MYOCHEL ).Board-certified in both neurology and physical medicine & rehabilitation, Dr. Yochelson has spent decades at the forefront of helping patients recover from some of the most complex neurological injuries. Prior to Shepherd Center, he held major leadership roles at MedStar National Rehabilitation Network and Georgetown University, where he also founded and led a Brain Injury Medicine Fellowship program.Earlier in his career, Dr. Yochelson served for over a decade in the United States Navy, including leadership roles in neurology and rehabilitation medicine.In addition to his clinical and academic work, Dr. Yochelson serves on the Board of Governors of the American Academy of Physical Medicine and Rehabilitation ( https://www.aapmr.org/ ), where he chairs the Inclusion and Engagement Committee, helping shape the future of a specialty dedicated not just to treating disease—but restoring function, independence, and quality of life.Important Episode Link - Understanding Spasticity: A Simple Guide to Symptoms, Treatment, and Getting Better - https://www.aapmr.org/resources/AAPMR_Spasticity_Patient_Journey.html#Physiatry #RehabilitationMedicine #AAPMR #Neurorehabilitation #BrainInjury #StrokeRecovery #SpinalCordInjury #Mobility #Function #QualityOfLife #Neuroplasticity #RecoveryScience #FutureOfMedicine #HealthcareInnovation #PatientRecovery #DisabilityCare #HumanPerformance #Longevity #MedicinePodcast #HealthPodcast #SciencePodcast #ClinicalInnovation #MedicalEducation #RestoreFunctionSupport the show

Send us Fan MailLyme disease affects hundreds of thousands of people every year—and yet we still struggle to diagnose it, treat it, and prevent it.David Walsey is a strategic biotech leader with more than two decades of experience helping public life sciences companies translate scientific innovation into market impact. As Executive Director of the Bay Area Lyme Foundation ( https://www.bayarealyme.org/ ), David leads national efforts to accelerate research, improve diagnostics, and expand access to effective treatments for Lyme disease and other tick-borne illnesses—an area of growing public health urgency.Prior to joining the Foundation, David served as Senior Vice President of Corporate Affairs at MEI Pharma, where he oversaw corporate strategy, investor relations, and communications during a critical period for the company. His career spans leadership roles across the biotech ecosystem, including Alder Biopharmaceuticals, Optimer Pharmaceuticals, Sarepta Therapeutics, Arena Pharmaceuticals, and Maxim Pharmaceuticals, as well as strategic communications roles at agencies such as Real Chemistry (formerly W2O Group), The Ruth Group, and Noonan Russo.David began his professional journey as a practicing attorney in New York City, bringing a legal and financial lens to his later work in biotech leadership. He holds an LL.M. in Taxation from New York University School of Law, a J.D. from Brooklyn Law School, and a B.A. from Franklin and Marshall College.#LymeDisease #LymeVaccine #Pfizer #Biotech #VaccineScience #PublicHealth #TickBorneDisease #MedicalInnovation #Biotechnology #Healthcare #InfectiousDisease #ClinicalTrials #VLA15 #Pharma #DrugDevelopment #SciencePodcast #Longevity #Diagnostics #VenturePhilanthropy #BayAreaLyme #FutureOfMedicine #BioInnovation #HealthcareInnovation #MedicalResearchSupport the show

Send us Fan MailFor decades, male birth control has remained one of medicine’s most elusive goals. Now, a new non-hormonal pill is entering human trials—and could finally change the balance of reproductive responsibilityAkash Bakshi is CEO and Co-Founder of YourChoice Therapeutics ( https://www.yourchoicetx.com/ ), a company working to develop the first hormone-free birth control pill for men.Akash’s work sits at the intersection of biotechnology innovation, reproductive health, and social change. His team is advancing YCT-529, a first-in-class non-hormonal contraceptive currently in human clinical trials, designed to safely and reversibly suppress sperm production by targeting retinoic acid signaling.Before founding YourChoice, Akash held leadership roles across biotech and drug development, including serving as CEO of ANA Therapeutics, where he rapidly advanced a COVID-19 therapeutic into clinical trials and led the company through acquisition, as well as COO of NeuroBo Pharmaceuticals.Earlier in his career, Akash worked at University of California, Berkeley helping bridge early-stage science and commercialization—experience that clearly shaped his approach to translating breakthrough academic research into real-world therapies.At a time when contraceptive responsibility has largely fallen on women—and amid growing debates around reproductive rights—Akash and his team are trying to fundamentally reshape the landscape.#MaleBirthControl #BirthControlPillForMen #NonHormonalContraception #YCT529 #BiotechBreakthrough #FutureOfMedicine #ReproductiveHealth #MensHealth #WomensHealth #FertilityScience #PharmaInnovation #ClinicalTrials #BiotechStartups #HealthcareInnovation #EndUnintendedPregnancy #SciencePodcast #LongevityAndHealth #DrugDevelopment #MedicalBreakthrough #ContraceptionRevolution #FutureOfHealthcare #RARalpha #YourChoiceTherapeutics #BiotechCEO #HealthTech #PostRoeWorldSupport the show

Send us Fan MailThere’s an animal that can rebuild its entire body structure in just a few days—and it might hold clues to a new kind of medicine.Eden Ben is CEO of Amorphical ( https://www.amorphical.com/ ), a pioneering biotech company out of Israel that’s been quietly building a completely new approach to mineral-based therapeutics.Founded in 2004, Amorphical has developed a proprietary nano-formulation of amorphous calcium carbonate—what they call ACC—engineered using biomimicry principles inspired by how certain organisms naturally stabilize calcium in highly bioavailable forms.What makes this so interesting is that ACC behaves very differently from traditional crystalline calcium. It’s dramatically more soluble, significantly more bioavailable, and appears to act not just as a supplement, but as a functional, bioactive material that can influence cellular and tissue-level processes.The company is leveraging this platform across a range of indications—from bone and metabolic diseases to inflammatory conditions—aiming to move beyond symptom management and toward addressing underlying biological mechanisms.Eden himself has had a fascinating journey with the company—from early business development and global market expansion, to leading clinical and product strategy, and now stepping into the CEO role to scale both the science and the business globally.#Biotech #Longevity #Geroscience #Calcium #Nanotechnology #Biomimicry #ExtracellularMatrix #CancerResearch #Inflammation #Osteoporosis #BoneHealth #FutureOfMedicine #LifeSciences #Biology #RegenerativeMedicine #HealthInnovation #StartupScience #DeepTech #MedicalBreakthrough #Podcast #SciencePodcast #IsraeliInnovation #NanoMedicine #AgingResearchSupport the show

Send us Fan MailWhat if AI didn’t need massive data centers—and could think more like the human brain?Sean Hehir is the Chief Executive Officer of BrainChip ( https://brainchip.com/ ), a pioneer in neuromorphic computing and ultra-low-power artificial intelligence hardware designed for intelligent edge devices.At BrainChip, Sean oversees the commercialization of the company’s Akida neuromorphic processor—an advanced AI chip inspired by the architecture of the human brain. Akida enables real-time machine learning and pattern recognition directly at the edge, dramatically reducing power consumption and latency compared to traditional cloud-based AI systems. The technology is now being explored for applications ranging from defense and autonomous systems to automotive sensing, robotics, and healthcare devices.Prior to joining BrainChip in 2021, Sean spent more than two decades in senior leadership roles across the enterprise computing and semiconductor ecosystem. Earlier in his career, Sean held several senior executive roles at Hewlett‑Packard, including Vice President of Strategic Alliances, where he managed some of the company’s most important global partnerships with industry giants such as Microsoft, Intel, Cisco Systems, Oracle, and SAP.His earlier leadership experience also includes roles at Fusion‑io and Compaq, where he helped drive large-scale enterprise computing partnerships and global service provider strategies.Sean holds an MBA in Economics from Georgia State University and a Bachelor of Science in Business from University of Massachusetts Amherst.#AI #ArtificialIntelligence #NeuromorphicComputing #BrainInspiredAI #EdgeAI #FutureOfAI #AIHardware #TechInnovation #DefenseTech #AutonomousSystems #MachineLearning #DeepLearning #NextGenAI #QuantumComputing #Semiconductors #Robotics #SmartSensors #AIRevolution #EmergingTech #HealthcareAI #WearableTech #MilitaryTechnology #Innovation #FutureTech #PodcastSupport the show

Send us Fan MailNorberto Chaclin is Executive Vice President, Chief Research & Development Officer of Mondelēz International ( https://www.mondelezinternational.com/about-us/leadership/executive-team/norberto-chaclin/ ), a global snacking leader with 2025 net revenues of approximately $38.5 billion, driven by iconic brands such as Oreo, Ritz, LU, Clif Bar and Tate's Bake Shop biscuits and baked snacks, as well as Cadbury Dairy Milk, Milka and Toblerone chocolate. Norberto most recently served as the Company’s Senior Vice President, R&D, Global Biscuits and Regional R&D partner for North America. Under his leadership, Mondelēz rolled out exciting innovations and renovations across some of its most iconic biscuit and baked snack brands. Previously, he led R&D for the Company’s global gum and candy business. Before joining Mondelēz International, Norberto spent 18 years with PepsiCo in a series of progressively responsible roles spanning Frito-Lay North America, PepsiCo International, Global Beverages and Joint Ventures – ultimately leading R&D for PepsiCo North America Beverages and the Pepsi/Starbucks joint venture. An amateur chef and native of Curaçao, Netherlands Antilles, Norberto brings to the role a passion for culinary arts and traditions. He holds a bachelor’s degree in chemical engineering from Texas A&M University and a master’s degree in business administration from Southern Methodist University. He serves on the Board of Torr FoodTech and on the Board of Trustees for IAFNS – Advancing Food and Nutrition Sciences.Important Episode Link Mondelēz International's State of Snacking reports - https://www.mondelezinternational.com/stateofsnacking/#FutureOfFood #FoodTech #Snacking #Mondelez #Oreo #Cadbury #Chocolate #FoodInnovation #CPG #FMCG #AI #PrecisionFermentation #Sustainability #HealthySnacks #FoodScience #ConsumerTrends #GenZ #SupplyChain #FoodFuture #InnovationSupport the show

Send us Fan MailAdam Molnar is Co-Founder, COO and Vice President of Strategic Partnerships at Neurable ( https://www.neurable.com/ ), a pioneering neurotechnology company developing real-time brain-computer interface systems that translate neural signals into actionable insights.Over the past decade, Adam and his team have been working at the frontier of non-invasive EEG-based brain-computer interfaces, building technology capable of measuring cognitive states such as workload, fatigue, and attention directly from brain activity. Neurable’s platform has attracted over $40 million in funding and has led to collaborations with organizations including the U.S. Air Force, the Air Force Research Laboratory, and U.S. Army, where the technology is being evaluated for applications ranging from pilot training and human performance monitoring to the detection of blast-related mild traumatic brain injury.Adam leads the company’s global strategic partnerships across both commercial and defense sectors, helping bring neurotechnology out of the lab and into real-world environments—from wearable computing platforms to operational military systems. His work sits at the intersection of AI, neuroscience, and human-machine teaming, exploring how brain data can improve safety, cognition, and performance in high-stakes environments.Beyond Neurable, Adam contributes to the global neurotechnology ecosystem through organizations like NeuroTechX and the Institute of Neuroethics, helping shape the future of neural data governance and ethical brain-computer interfaces. He has also been recognized as part of Forbes 30 Under 30 for his work in advancing consumer neurotechnology.Today we’ll explore how brain-computer interfaces are moving beyond laboratories and into operational systems—from defense training environments to everyday wearable devices—and what it means when machines can finally begin to understand the human brain in real time.#neurotechnology #BCI #artificialintelligence #futuretech #wearables #braincomputerinterface #AI #defensetech #militaryinnovation #humanperformance #neuroscience #neuroethics #emergingtechnology #innovation #podcast #techtalk #longevity #healthtech #digitalhealth #futureofworkSupport the show

Send us Fan MailModern warfare is changing—and it’s not just about weapons anymore.The real battle may be logistics, and autonomous systems are about to transform how wars are fought and sustained.Brandon Florian is Co-Founder and Chief Commercial Officer of Grid Aero ( https://www.grid.aero/ ), a venture-backed aerospace and defense startup building low-cost, autonomous aircraft designed for long-range operations and resilient logistics.Brandon has spent more than two decades working at the intersection of aerospace engineering, national security strategy, and emerging defense technologies. His career spans engineering, business development, and technology scouting across both large defense primes and the startup ecosystem.Brandon began his career as a spacecraft engineer at General Dynamics working on space systems before moving into strategic roles at Northrop Grumman, where he focused on innovation, disruptive technology scouting, and growth strategy. He later joined Starburst Aerospace, one of the leading global accelerators for aerospace and defense startups, where he helped build international innovation programs—including collaborations between the U.S. Space Force and the UK Ministry of Defense.Brandon has also worked extensively in venture and startup ecosystems through Mandala Space Ventures and independent consulting, helping governments and corporations navigate the rapidly evolving landscape of defense innovation.Today at Grid Aero, Brandon is focused on a critical challenge shaping modern warfare: how to build resilient logistics networks capable of operating in contested environments using autonomy, distributed systems, and radically lower-cost platforms.With a background in aerospace engineering from UCLA and an MBA from Pepperdine, Brandon brings both technical depth and strategic insight into how emerging technologies—from autonomous aircraft to distributed supply networks—will shape the future of defense operations.#defensetech #militaryinnovation #futureofwar #autonomy #AI #nationalsecurity #military #aerospace #drones #logistics #warstrategy #china #taiwan #iran #pentagon #startups #innovation #technology #supplychain #geopoliticsSupport the show